Arcellx Acquisition Clears Final Regulatory Hurdles, Tender Offer Extended Amid High Valuation Concerns

What happened

Arcellx, a clinical-stage biotech developing the BCMA-targeting CAR-T therapy anito-cel in partnership with Gilead/Kite, has been under scrutiny in the DeepValue report for its high valuation at $68 despite no BLA filed and unproven durability versus rivals like Carvykti. On April 17, 2026, Gilead announced that all required regulatory approvals for its acquisition of Arcellx have been obtained, including from the Australian Competition and Consumer Commission, and the tender offer expiration has been extended. This milestone removes a key overhang for the deal, which the report flagged as a risk due to Arcellx's single-asset dependence and partnership stability. However, the DeepValue report critically notes that current pricing already discounts timely drug approval, and the acquisition approval does not address underlying issues such as collapsing collaboration revenue or the need for longer-term safety data. Investors must now evaluate whether the tender offer price aligns with the report's base case value of $75 or if it reflects inflated sentiment from a crowded bullish narrative.

Implication

With regulatory approvals secured, the acquisition is likely to proceed, providing a liquidity event that could lock in gains for shareholders near current prices. However, the DeepValue report emphasizes that at $68, Arcellx's stock already embeds high expectations for anito-cel's approval and launch, so the tender offer price must be critically compared to the base case implied value of $75. The extension of the tender offer suggests Gilead's commitment, but propaganda around this milestone may obscure persistent risks like BLA filing delays, unproven durability versus Carvykti, and steep cash burn. Investors should be wary of sentiment-driven optimism, as the report's WAIT rating and attractive entry at $55 indicate that the acquisition does not eliminate the need for clearer regulatory visibility or better risk-adjusted entry points. Ultimately, while the news de-risks the deal completion, it does not change the core investment thesis that Arcellx remains overvalued relative to its binary clinical and commercial uncertainties.

Thesis delta

The previous thesis centered on waiting for clearer regulatory milestones on anito-cel's BLA and durability data before investing, given high valuation and crowded sentiment. With acquisition approvals now secured, the thesis shifts to evaluating the tender offer price against intrinsic value, but critical concerns about drug efficacy, safety, and competitive positioning remain unresolved, keeping the risk-reward skewed negatively without a pullback or better terms.